Targeting JAK2 in the therapy of myeloproliferative neoplasms

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

(2011) P. Guglielmelli et al.   BLOOD

How I treat myelofibrosis

(2011) A. Tefferi   BLOOD

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

(2011) E. A. Nelson et al.   BLOOD

JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective

(2011) A. Tefferi et al.   BLOOD REVIEWS

JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

(2011) Fan Liu et al.   CANCER CELL

Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells

(2011) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

(2011) T. Hornakova et al.   HAEMATOLOGICA

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

(2011) Anthony D. William et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue

(2011) V. Novotny-Diermayr et al.   MOLECULAR CANCER THERAPEUTICS

Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control

(2011) H Jäkel et al.   ONCOGENE

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia

(2010) C. R. Rinaldi et al.   BLOOD

Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells

(2010) X. Wang et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis

(2010) J. D. Roll et al.   CANCER RESEARCH

Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway

(2010) Min Lu et al.   EXPERIMENTAL HEMATOLOGY

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

(2010) Sachie Marubayashi et al.   JOURNAL OF CLINICAL INVESTIGATION

NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases

(2010) M M Reddy et al.   LEUKEMIA

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes

(2010) A. J. Levine et al.   SCIENCE

Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

(2009) L. S. Chen et al.   BLOOD

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

(2009) Y. Wang et al.   BLOOD

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms

(2009) Lizz F. Grimwade et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK2 Gets Histone H3 Rolling

(2009) Martin Sattler et al.   CANCER CELL

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation

(2009) Jacob P. Laubach et al.   EXPERIMENTAL HEMATOLOGY

STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant

(2009) Megumi Funakoshi-Tago et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis

(2008) Jin Lee   ANNALS OF HEMATOLOGY

Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications

(2008) Margret S. Rodrigues et al.   ANTIOXIDANTS & REDOX SIGNALING

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

(2008) G. Wernig et al.   BLOOD

Myeloproliferative disorders

(2008) R. L. Levine et al.   BLOOD

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Enhanced histone deacetylase enzyme activity in primary myelofibrosis

(2008) Jen Chin Wang et al.   LEUKEMIA & LYMPHOMA

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth

(2008) B. Clem et al.   MOLECULAR CANCER THERAPEUTICS